Trends in cannabis use among U.S. adults amid the COVID-19 pandemic.


Journal

The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759

Informations de publication

Date de publication:
02 2022
Historique:
received: 22 06 2021
revised: 18 10 2021
accepted: 20 10 2021
pubmed: 12 12 2021
medline: 4 2 2022
entrez: 11 12 2021
Statut: ppublish

Résumé

The COVID-19 pandemic has had an impact on mental health and alcohol use in the US, however there is little research on its impacts on cannabis use. Considering the role of cannabis as a coping strategy or self-medicating behavior, there is a need to understand how individuals who use cannabis have adapted their use amid the pandemic. Therefore, this study examined changes in self-reported cannabis use among US adults in the context of COVID-19 pandemic by (1) describing trends of use during the first 8 months of the pandemic among adults who used cannabis in this period; and (2) characterizing trends of use within sociodemographic subgroups and by state cannabis policy status. The sample consisted of 1,761 US adults who used cannabis at least once during the 8-month study period from the nationally representative Understanding America Study. Linear mixed-effect models were used to model changes in the number of days of past-week cannabis use across 16 waves from March 10, 2020, to November 11, 2020. Compared to early March, the number of days cannabis was used per week was significantly higher at the start of April (β=0.11, 95% CI=0.03, 0.18) and May (β=0.21,95% CI=0.05, 0.36). In subsequent months (June - November), the number of days of cannabis use attenuated to levels comparable to March. Trends of cannabis use across the study period generally did not differ across sociodemographic characteristics and state cannabis policy status. Though increases in use were marginal among many groups, the evolving pandemic and the growing concern for the mental health of segments of the U.S. population warrant close monitoring of coping behaviors, including substance use.

Sections du résumé

BACKGROUND
The COVID-19 pandemic has had an impact on mental health and alcohol use in the US, however there is little research on its impacts on cannabis use. Considering the role of cannabis as a coping strategy or self-medicating behavior, there is a need to understand how individuals who use cannabis have adapted their use amid the pandemic. Therefore, this study examined changes in self-reported cannabis use among US adults in the context of COVID-19 pandemic by (1) describing trends of use during the first 8 months of the pandemic among adults who used cannabis in this period; and (2) characterizing trends of use within sociodemographic subgroups and by state cannabis policy status.
METHODS
The sample consisted of 1,761 US adults who used cannabis at least once during the 8-month study period from the nationally representative Understanding America Study. Linear mixed-effect models were used to model changes in the number of days of past-week cannabis use across 16 waves from March 10, 2020, to November 11, 2020.
RESULTS
Compared to early March, the number of days cannabis was used per week was significantly higher at the start of April (β=0.11, 95% CI=0.03, 0.18) and May (β=0.21,95% CI=0.05, 0.36). In subsequent months (June - November), the number of days of cannabis use attenuated to levels comparable to March. Trends of cannabis use across the study period generally did not differ across sociodemographic characteristics and state cannabis policy status.
CONCLUSION
Though increases in use were marginal among many groups, the evolving pandemic and the growing concern for the mental health of segments of the U.S. population warrant close monitoring of coping behaviors, including substance use.

Identifiants

pubmed: 34894469
pii: S0955-3959(21)00435-7
doi: 10.1016/j.drugpo.2021.103517
pmc: PMC8653409
mid: NIHMS1763181
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

103517

Subventions

Organisme : NIMH NIH HHS
ID : T32 MH109436
Pays : United States
Organisme : NIA NIH HHS
ID : T32 AG000247
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA007292
Pays : United States
Organisme : CIHR
Pays : Canada
Organisme : NIMH NIH HHS
ID : T32 MH122357
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declarations of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Bone Marrow Transplant. 2020 Apr;55(4):675-680
pubmed: 31576022
Nutrients. 2020 Jun 02;12(6):
pubmed: 32498323
JAMA Netw Open. 2020 Sep 1;3(9):e2022942
pubmed: 32990735
J Addict Med. 2021 Jul-Aug 01;15(4):341-344
pubmed: 33105169
J Am Acad Child Adolesc Psychiatry. 2020 Nov;59(11):1218-1239.e3
pubmed: 32504808
JAMA Psychiatry. 2017 Jun 1;74(6):579-588
pubmed: 28445557
Eur Addict Res. 2020;26(6):309-315
pubmed: 32961535
J Behav Exp Finance. 2020 Sep;27:100341
pubmed: 32427215
Subst Abus. 2020;41(4):409-412
pubmed: 33044893
J Med Internet Res. 2020 Jun 17;22(6):e20185
pubmed: 32519963
J Racial Ethn Health Disparities. 2021 Oct;8(5):1300-1314
pubmed: 33057998
Addiction. 2021 Oct;116(10):2770-2778
pubmed: 33730400
Psychiatry Res. 2020 Aug;290:113117
pubmed: 32480121
JAMA Netw Open. 2020 Sep 1;3(9):e2019686
pubmed: 32876685
Psychiatry Res. 2020 Aug;290:113172
pubmed: 32512357
Am J Drug Alcohol Abuse. 2019;45(6):623-643
pubmed: 30870044
J Addict Med. 2021 Nov-Dec 01;15(6):484-490
pubmed: 33323693
Am J Public Health. 2020 Nov;110(11):1628-1634
pubmed: 32941066
Front Psychiatry. 2020 Dec 21;11:601653
pubmed: 33408655
Addiction. 2022 Feb;117(2):331-340
pubmed: 34159674
J Clin Nurs. 2020 Aug;29(15-16):2756-2757
pubmed: 32250493
J Addict Dis. 2021 Jan-Mar;39(1):26-36
pubmed: 32933383
Gerontol Geriatr Med. 2018 Jun 21;4:2333721418781668
pubmed: 29977980
JAMA. 2020 Jul 7;324(1):93-94
pubmed: 32492088
JMIR Public Health Surveill. 2020 Sep 18;6(3):e19630
pubmed: 32589149

Auteurs

Savannah G Brenneke (SG)

Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, 624N Broadway, Baltimore, MD 21205, USA. Electronic address: sbrenne7@jhu.edu.

Courtney D Nordeck (CD)

Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, 624N Broadway, Baltimore, MD 21205, USA.

Kira E Riehm (KE)

Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, 624N Broadway, Baltimore, MD 21205, USA.

Ian Schmid (I)

Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, 624N Broadway, Baltimore, MD 21205, USA.

Kayla N Tormohlen (KN)

Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, 624N Broadway, Baltimore, MD 21205, USA.

Emily J Smail (EJ)

Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, 624N Broadway, Baltimore, MD 21205, USA.

Renee M Johnson (RM)

Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, 624N Broadway, Baltimore, MD 21205, USA.

Luther G Kalb (LG)

Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, 624N Broadway, Baltimore, MD 21205, USA; Department of Neuropsychology, Kennedy Krieger Institute, Johns Hopkins University, 1750 E Fairmount Ave, Baltimore, MD 21231, USA.

Elizabeth A Stuart (EA)

Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, 624N Broadway, Baltimore, MD 21205, USA.

Johannes Thrul (J)

Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, 624N Broadway, Baltimore, MD 21205, USA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA; Centre for Alcohol Policy Research, La Trobe University, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH